High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival

Clinical Cancer Research

Volumn 11, Issue 18, 2005, Pages 6520-6527

  Van Rhenen, Anna ^a   Feller, Nicole ^a   Kelder, Angèle ^a   Westra, August H ^a   Rombouts, Elwin ^b   Zweegman, Sonja ^a   Van Der Pol, Marjolein A ^a   Waisfisz, Quinten ^a   Ossenkoppele, Gert J ^a   Schuurhuis, Gerrit Jan ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANTIGEN DETECTION; ARTICLE; CANCER SURVIVAL; CELL SURVIVAL; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADP-RIBOSYL CYCLASE; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD34; ANTIGENS, CD38; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR STEM CELLS;

EID: 25144433295     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0468     Document Type: Article

References (43)

1. Lowenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology (AmSoc Hematol Educ Program) 2003;82-101.
2. Feller N, van der Pol MA, van Stijn A, et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004;18:1380-90.
3. San Miguel JF, Vidriales MB, Lopez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001;98:1746-51.
4. Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000;96:3948-52.
5. Kern W, Voskova D, Schoch C, et al. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004;104:3078-85.
6. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
7. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 1999;94:1761-72.
8. Grimwade D, Enver T. Acute promyelocytic leukemia: where does it stem from? Leukemia 2004;18:375-84.
9. Warner JK, Wang JC, Hope KJ, Jin L, Dick JE. Concepts of human leukemic development. Oncogene 2004;23:7164-77.
10. Kanda Y, Hamaki T, Yamamoto R, et al. The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer 2000;88:2529-33.
11. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62.
12. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20.
13. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10:1911-8.
14. Rombouts WJ, Martens AC, Ploemacher RE. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. Leukemia 2000;14:889-97.
15. Versiegen MM, Wognum AW, Wagemaker G. Thrombopoietin is a major limiting factor for selective outgrowth of human umbilical cord blood cells in non-obese diabetic/severe combined immunodeficient recipient mice. Br J Haematol 2003;122:837-46.
16. + cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica 2003;88:983-93.
17. + hematopoietic stem and progenitor cells. European Working Group on Clinical Cell Analysis. Cytometry 1998;34:128-42.
18. van der Pol MA, Broxterman HJ, Westra G, Ossenkoppele GJ, Schuurhuis GJ. Novel multiparameter flow cytometry assay using Syto16 for the simultaneous detection of early apoptosis and apoptosis-corrected P-glycoprotein function in clinical samples. Cytometry 2003;556:14-21.
19. Lacombe F, Durrieu F, Briais A, et al. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 1997;11:1878-86.
20. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor α chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000;14:1777-84.
21. van der Pol MA, Pater JM, Feller N, et al. Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia. Leukemia 2001;15:1554-63.
22. Sutherland H, Blair A, Vercauteren S, Zapf R. Detection and clinical significance of human acute myeloid leukaemia progenitors capable of long-term proliferation in vitro. Br J Haematol 2001;114:296-306.
23. Keyhani A, Huh YO, Jendiroba D, et al. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk Res 2000;24:153-9.
24. Monaco G, Konopleva M, Munsell M, et al. Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells 2004;22:188-201.
25. +/. Cancer Res 2000;60:4403-11.
26. Terstappen LW, Safford M, Unterhalt M, et al. Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells. Leukemia 1992;6:993-1000.
27. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003;101:3142-9.
28. San Miguel JF, Martinez A, Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997;90:2465-70.
29. van der Pol MA, Broxterman HJ, Pater JM, et al. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica 2003;88:134-47.
30. Ong YL, McMullin MF, Bailie KE, et al. High bax expression is a good prognostic indicator in acute myeloid leukaemia. Br J Haematol 2000;111:182-9.
31. Estrov Z, Thall PF, Talpaz M, et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 1998;92:3090-7.
32. Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie JP. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 1999;94:1046-56.
33. van der Kolk DM, de Vries EG, van Putten WJ, et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 2000;6:3205-14.
34. van Stijn A, Feller N, Kok A, et al. Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis. Clin Cancer Res 2005;11:2540-6.
35. Geller RB, Zahurak M, Hurwitz CA, et al. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10). Br J Haematol 1990;76:340-7.
36. Guinot M, Sanz GF, Sempere A, et al. Prognostic value of CD34 expression in de novo acute myeloblastic leukaemia. Br J Haematol 1991;79:533-4.
37. Selleri C, Notaro R, Catalano L, et al. Prognostic irrelevance of CD34 in acute myeloid leukaemia. Br J Haematol 1992;82:479-81.
38. Bradstock K, Matthews J, Benson E, Page F, Bishop J. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 1994;84:1220-5.
39. Kyoda K, Nakamura S, Hattori N, et al. Lack of prognostic significance of CD34 expression in adult AML when FAB MO and M3 are excluded. Am J Hematol 1998;57:265-6.
40. Haferlach T, Schoch C, Loffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003;21:256-5.
41. - leukemic progenitors. Leukemia 1999;13:1513-8.
42. Eakker AB, van den OS, Bakker AQ, et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 2004;64:8443-50.
43. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.